AIDX
20/20 Biolabs, Inc. Common Stock
NASDAQ · Healthcare · Medical - Devices · US
$0.59
−3.27%Year over year
Reported trailing growth
- Revenue
- +23.5%
- EBITDA
- +27.1%
- EBIT
- +34.7%
- EPS
- +46.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -3.9%
- EBITDA
- +80.7%
- EPS
- +82.9%
Three-year CAGR
- Revenue
- -43.0%
- EBITDA
- +36.6%
- EBIT
- +41.2%
- Net income
- +32.7%
- EPS
- +48.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026